PDCD1 and head and neck cancer: Indeed, we have demonstrated that restoration of p53 function via SGT-53 can improve anti-PD-1 immunotherapy of several immune-resistant mouse tumors including head and neck cancer, breast cancer, and glioma [34,35,36].